Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine

Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine

Background: We have designed a prospective study aiming to monitor the immune response in 178 health care workers six months after BNT162b2 mRNA vaccination. Methods: The humoral immune response of all subjects was evaluated by chemiluminescence (CMIA); in 60 serum samples, a live virus-based neutra...

Full description

Bibliographic Details
Main Authors:	Claudia Gandolfo, Gabriele Anichini, Marco Mugnaini, Monica Bocchia, Chiara Terrosi, Anna Sicuranza, Gianni Gori Savellini, Alessandro Gozzetti, Federico Franchi, Maria Grazia Cusi
Format:	Article
Language:	English
Published:	MDPI AG 2022-01-01
Series:	Vaccines
Subjects:	SARS-CoV-2 BNT162b2 mRNA vaccine humoral immunity cellular immunity fuzzy system
Online Access:	https://www.mdpi.com/2076-393X/10/2/171

Similar Items

Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees
by: Gabriele Anichini, et al.
Published: (2022-05-01)

Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients
by: Antti Hurme, et al.
Published: (2022-04-01)

Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection
by: Simona Arientová, et al.
Published: (2023-10-01)

Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine
by: Gabriele Anichini, et al.
Published: (2022-09-01)

Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
by: Jonas Herzberg, et al.
Published: (2022-05-01)

A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients
by: Jan Melin, et al.
Published: (2022-10-01)

Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
by: Theano Lagousi, et al.
Published: (2022-07-01)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
by: Evangelos Terpos, et al.
Published: (2022-02-01)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
by: Yana Davidov, et al.
Published: (2022-12-01)

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection
by: Omid Rezahosseini, et al.
Published: (2023-01-01)

BNT162b2 COVID-19 vaccination elicited protective robust immune responses in pediatric patients with inborn errors of metabolism
by: Tanyel Zubarioglu, et al.
Published: (2023-01-01)

Antibody response after two doses of the BNT162b2 vaccine among healthcare workers of a Greek Covid 19 referral hospital: A prospective cohort study
by: Areti Tychala, et al.
Published: (2022-05-01)

Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination
by: Brent Appelman, et al.
Published: (2021-10-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
by: Evangelos Terpos, et al.
Published: (2021-10-01)

Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine – A Prospective Observational Study
by: Jonas Herzberg, et al.
Published: (2022-07-01)

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult
by: Mazin Barry, et al.
Published: (2022-01-01)

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
by: Giuseppe A. Palumbo, et al.
Published: (2023-02-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
by: Eli Magen, et al.
Published: (2022-07-01)

Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents
by: Palittiya Sintusek, et al.
Published: (2022-08-01)

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
by: Areti Tychala, et al.
Published: (2021-12-01)

Profound decline of antibody titers 6 months after BNT162b2 vaccination in healthy volunteers
by: Kozakai Rikei, et al.
Published: (2022-04-01)

Effect of SARS-CoV-2 Infection and BNT162b2 Vaccination on the mRNA Expression of Genes Associated with Angiogenesis
by: Paulina Wigner-Jeziorska, et al.
Published: (2023-11-01)

Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study
by: Keita Yamashita, et al.
Published: (2022-06-01)

Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines
by: Roberta Mancuso, et al.
Published: (2022-10-01)

Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center
by: Maria Costantino, et al.
Published: (2022-03-01)

Good Immunogenicity of Delayed Second Dose of BNT162b2 Vaccine in Individuals with Acute Allergic-like Reactions after the First Dose
by: Kazuhiro Araki, et al.
Published: (2022-12-01)

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
by: Luigia Trabace, et al.
Published: (2022-04-01)

Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report
by: Tzu-Chien Lin, et al.
Published: (2023-06-01)

Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima
by: Yurie Kobashi, et al.
Published: (2022-11-01)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
by: Ahmed Zaqout, et al.
Published: (2021-07-01)

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
by: Daniel Leung, et al.
Published: (2022-09-01)

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
by: Anna Kaznadzey, et al.
Published: (2022-04-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)

Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?
by: Giulia Renisi, et al.
Published: (2021-09-01)

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
by: Lorenzo Azzi, et al.
Published: (2022-01-01)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
by: Jolanta Kiewisz, et al.
Published: (2022-04-01)

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers
by: Khetam Hussein, et al.
Published: (2022-10-01)

Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review
by: Karen Cortés-Sarabia, et al.
Published: (2022-06-01)